BOCIC(SH:601696) Xin Lang Cai Jing·2025-08-28 06:21Group 1 - The core point of the news is the decline in the stock price of Beijing Baipusi Biotechnology Co., Ltd., which fell by 5.21% to 53.35 CNY per share, with a total market capitalization of 8.955 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] - The trading volume for the stock was 115 million CNY, with a turnover rate of 1.65% [1] Group 2 - According to data, a fund under Bank of China Securities holds a significant position in Baipusi, with 99,000 shares, accounting for 4.48% of the fund's net value, making it the seventh-largest holding [2] - The fund, named Bank of China Securities Health Industry Mixed Fund (002938), has a total scale of 158 million CNY and has achieved a return of 58.4% this year, ranking 284 out of 8191 in its category [2] - The fund manager, Li Mingwei, has been in position for 2 years and 189 days, with the best and worst fund returns during his tenure both recorded at 6.58% [3]